Pharmacy World & Science

, Volume 29, Issue 2, pp 47–50 | Cite as

Provision of pharmaceuticals in Australian hospitals: equity of access?

  • Gisselle Gallego
  • Susan J. Taylor
  • Jo-anne E. Brien
Commentary

Abstract

In Australia, medicines are funded under a complex set of financial arrangements. Currently there are dual funding arrangements in public and private hospitals that can lead to differences in patient access to medications. There are considerable concerns about the consequences of the fragmentation and “lack of cohesion of the system”. Some decision-makers consider there are inequities because of the funding models in place. What follows is a description of this system.

Keywords

Australia Funding Hospitals Medicines Pharmaceuticals 

References

  1. 1.
    Salked G, Mitchell A, Hill S. Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian health policy. St Leonards: Allen & Unwin; 1999. ISBN 1 86448 749 6Google Scholar
  2. 2.
    Commonwealth Department of Health and Ageing. National medicines policy. 2000; http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-objectives-policy.htm/$FILE/nmp2000.pdf (7 September 2006)Google Scholar
  3. 3.
    Department of Health and Ageing. TGA – therapeutics goods administration. 2006; http://www.tga.gov.au/docs/html/pmeds_reg.htm (7 September 2006)Google Scholar
  4. 4.
    Duckett SJ. Australian hospital services: An overview. Aust Health Rev 2002; 25(1):2–18Google Scholar
  5. 5.
    Department of Health Government of Western Australia. Pharmaceutical benefit scheme (PBS) reform. 2006; http://www.health.wa.gov.au/pbsreform/ (7 September 2006)Google Scholar
  6. 6.
    Department of Health and Ageing. Annual report 2003–2004. Australian health care agreements. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/14C0682D7DFA0F66CA25718E001BCBCC/$File/ar2003-04_full.pdf (7 September 2006)Google Scholar
  7. 7.
    Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004; 28(2):194–205PubMedCrossRefGoogle Scholar
  8. 8.
    Commonwealth Department of Health and Aged Care. Guidelines for the pharmaceutical industry preparation of submissions to the Pharmaceutical Benefits advisory committee. Canberra: Commonwealth Department of Health and Ageing; 2002. ISBN 0 642 82144 5Google Scholar
  9. 9.
    Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits – Section 100 arrangements. 2006; http://www.health.gov.au/internet/wcms/publishing.nsf/content/pbs-schedule-sec100 (7 September 2006)Google Scholar
  10. 10.
    Victorian Government Health Information. Commonwealth/State highly specialised drugs program guidelines. 2006; http://www.health.vic.gov.au/hsdp/program.htm#Anchor-Program-5249 (7 September 2006)Google Scholar
  11. 11.
    Donato R, Scotton R. The Australian health care system. In: Mooney G, Scotton R. editors. Economics and Australian health policy. St Leonards, NSW: Allen & Unwin; 1999. ISBN 1 86448 749 6Google Scholar
  12. 12.
    Department of Health and Ageing. Australian health care agreements. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/Australian+Health+Care+Agreements-1 (7 September 2006)Google Scholar
  13. 13.
    Department of Health and Ageing. The state of our public hospitals, June 2004 report. http://www.health.gov.au/internet/WCMS/publishing.nsf/Content/health-ahca-sooph-index.htm/$FILE/sooph2004.pdf (7 September 2006)Google Scholar
  14. 14.
    Australian Institute of Health and Welfare (AIHW). Australia’s health 2004. Canberra: AIHW; 2004. ISBN 1 74024 382 XGoogle Scholar
  15. 15.
    Australian Bureau of Statistics. Year book Australia. Health care delivery and financing. 2006; http://www.abs.gov.au/Ausstats/abs@.nsf/94713ad445ff1425ca25682000192af2/98de259e1e8f1cb3ca256f7200832f37!OpenDocument (7 September 2006)Google Scholar
  16. 16.
    McAuley I. Stress on public hospitals – why private insurance has made it worse. Canberra: Australian Consumers Association and the Australian Healthcare Association; 2004Google Scholar
  17. 17.
    Blendon RJ, Schoen C, DesRoches CM, Osborn R, Zapert K, Raleigh E. Confronting competing demands to improve quality: a five-country hospital survey. Health Aff 2004; 23(3):119–135CrossRefGoogle Scholar
  18. 18.
    Royal Australasian College of Physicians. Response to the senate inquiry into public hospital funding. Sydney: Royal Australasian College of Physicians; 1999Google Scholar
  19. 19.
    Duckett SJ, Jackson TJ. The new health insurance rebate: an inefficient way of assisting public hospitals. Med J Aust 2000; 172(9):439–442PubMedGoogle Scholar
  20. 20.
    The Society of Hospital Pharmacists of Australia (SHPA). Moving forward – the funding of medicines in Australia’s hospitals. Melbourne: The Society of Hospital Pharmacists of Australia (SHPA); 2004Google Scholar
  21. 21.
    National Health Strategy. Issues in pharmaceutical drug use in Australia. Issue paper no.4. Canberra: Department of Health, Housing and Community Services; 1992. ISBNGoogle Scholar
  22. 22.
    Commonwealth Department of Health and Aged Care. The Australian health care system, an outline. Canberra: ACT, Publications Unit, Commonwealth Department of Health and Aged Care; 2000. ISBN 0 642 44730 6Google Scholar
  23. 23.
    Victorian Therapeutic Advisory Group VicTAG. Hospital price and resource allocation review: good practice model for controlling medicines costs in hospitals. Melbourne: Victorian Therapeutics Advisory Group; 2004Google Scholar
  24. 24.
    Australian Institute of Health and Welfare (AIHW). Australian hospital statistics 2002–2003. Canberra: AIHW; 2004. ISBN 1036-613XGoogle Scholar
  25. 25.
    Commonwealth Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners – chemotherapy pharmaceuticals access program supplement. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/986ABF111B7A5183CA256F180048C850/$File/pbschemo_aug06.pdf (7 September 2006)Google Scholar
  26. 26.
    O’Leary KM, Allison YM. Pharmacy distribution service delivery models in use in Australian public. J Pharm Pract Res 2004; 34(2):114–121Google Scholar
  27. 27.
    Larmour I, Thomson WA, TSui MK, Weeks GR. Introduction of Pharmaceutical Benefits scheme reforms at three Victorian public health services. J Pharm Pract Res 2003; 33:204–207Google Scholar
  28. 28.
    Senate Community Affairs Reference Committee. Public founding and options for reform. First report. Canberra: Senate Community Affairs Reference Committee; 2000. ISBN 0 642 71044 9Google Scholar
  29. 29.
    Low J. Negotiating access to PBS medicines in public hospitals. Aust J Pharm 2003; 84(December):928Google Scholar
  30. 30.
    Department of Health Government of Western Australia. Western Australia drugs and therapeutics committee (WATAG). http://www.watag.org.au/home/ (7 September 2006)Google Scholar
  31. 31.
    Queensland Government (Queensland Health). Queensland health policy/guidelines. Availability of pharmaceuticals. http://www.health.qld.gov.au/phs/Documents/pas/566.pdf (7 September 2006)Google Scholar
  32. 32.
    Hall J. Incremental change in the Australian health care system. Health Aff 1999; 18(3):95–110CrossRefGoogle Scholar
  33. 33.
    Allinson Y. Funding of pharmaceuticals in public hospitals: PBS under the probe. Healthcover 2001; 11(2):58–63Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Gisselle Gallego
    • 1
  • Susan J. Taylor
    • 2
  • Jo-anne E. Brien
    • 2
    • 3
  1. 1.Centre for Health Economics Research and Evaluation (CHERE)University of Technology, SydneyBroadwayAustralia
  2. 2.Faculty of PharmacyThe University of SydneyCamperdownAustralia
  3. 3.Pfizer Australia Chair in Clinical Pharmacy (St Vincent’s Hospital), Therapeutics CentreDarlinghurstAustralia

Personalised recommendations